Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

18 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Moexipril Articles

US FDA approves Teva's generic Uniretic

19 March 2007

Schwarz Pharma's revenue up 4.6% in 2005

27 February 2006

Schwartz Pharma boosted by US sales

9 May 2005

Schwarz Pharma wins Univasc case

17 January 2005

Teva's generic Univasc cleared in USA

19 May 2003

Schwarz Pharma looks to have turned corner

12 November 2001

Teva of Israel posts 75% rise in net income as Copaxone sales rise

2 November 2001

Healthy first-half earnings growth for Germany's Schwarz Pharma

6 August 2001

Schwarz Pharma net income up 65% as operating loss narrows

21 February 2001

NCEs In 1995: A Good Range Of Novel Drugs

29 January 1996

Moexipril Takes On Other ACEIs On Price

29 January 1996

US FDA Approving Fewer NMEs, But Faster, In 1995

11 September 1995

Schwarz' Univasc Cheapest ACE Inhibitor?

17 July 1995

Schwartz Pharma; Univasc

22 May 1995

MOEX "APPROVABLE"

8 August 1994

SCHWARTZ RECEIVES APPROVABLE LETTER

30 May 1994

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • Neovacs moving forward in rheumatoid arthritis, say analysts

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS